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Abstract 
 
There were approximately 43,000 new cases of pancreatic ductal adenocarcinoma (PDAC) in 
the U.S. in 2010, and approximately 37,000 deaths. PDAC thus constitutes the fourth leading 
cause of cancer deaths, and PDAC patients have a dismal 5-year survival rate of 6%; 
approximately 75% of patients die within the first year after diagnosis. PDAC is notoriously 
resistant to chemotherapy and radiation and even with our best treatment options, a complete 
margin-negative surgical resection, few patients achieve long-term survival.  Despite these 
statistics, surprisingly only a small number of NCI-designated cancer centers have a specialized 
pancreatic cancer program. The creation of the IUPUI Signature Center for Pancreatic Cancer 
Research has been the foundation for putting IUPUI, the IU School of Medicine, Purdue 
University and the IU Simon Cancer Center at the forefront of pancreatic cancer treatment and 
research across the nation. The Signature Center, comprised of basic, translational and clinical 
researchers, represents the continuum of the disease from biological / molecular investigation to 
clinical trials. Funding from the Signature Center Initiative is being utilized to develop genetically 
engineered mouse models, generate orthotopic pancreatic cancer mouse models as well as  
provide funding for peer reviewed pilot projects.  Establishment and characterization of these in 
vivo models provides the groundwork to be used by all members in their translational research 
projects; support of pilot projects provides preliminary data and identification of projects to be 
used in a SPORE application.  Additionally, work has begun on a web portal to promote and 
educate both patients and clinicians about the IUSCC Pancreas Cancer Clinic which became 
operational in 2010.  Taken together these activities provide the infrastructure to support 
pancreas cancer research at IU across the continuum of bench to bedside to practice.  The 
availability of these resources to all members promotes inter-disciplinary collaborations aimed at 
increasing our understanding of pancreatic cancer so that advancements can be made in 
diagnosis, prevention and treatment of this malignancy.     
 
